| Targeting Xkr8 via nanoparticle-mediated in situ co-delivery of siRNA and chemotherapy drugs for cancer immunochemotherapy Y Chen, Y Huang, Q Li, Z Luo, Z Zhang, H Huang, J Sun, LXT Zhang, ... Nature nanotechnology 18 (2), 193-204, 2023 | 70 | 2023 |
| Tumor-Derived IL33 Promotes Tissue-Resident CD8+ T Cells and Is Required for Checkpoint Blockade Tumor Immunotherapy L Chen, R Sun, J Xu, W Zhai, D Zhang, M Yang, C Yue, Y Chen, S Li, ... Cancer immunology research 8 (11), 1381-1392, 2020 | 47 | 2020 |
| The IL-1 family in tumorigenesis and antitumor immunity R Sun, DS Gao, J Shoush, B Lu Seminars in cancer biology 86, 280-295, 2022 | 45 | 2022 |
| Prognostic significance of resident CD103+ CD8+ T cells in human colorectal cancer tissues W Hu, R Sun, L Chen, X Zheng, J Jiang Acta Histochemica 121 (5), 657-663, 2019 | 38 | 2019 |
| Polymeric micelles in cancer immunotherapy Z Wan, R Zheng, P Moharil, Y Liu, J Chen, R Sun, X Song, Q Ao Molecules 26 (5), 1220, 2021 | 37 | 2021 |
| Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment M Yang, W Du, L Yi, S Wu, C He, W Zhai, C Yue, R Sun, AV Menk, ... Oncoimmunology 9 (1), 1708064, 2020 | 37 | 2020 |
| Research advances in nanomedicine, immunotherapy, and combination therapy for leukemia Z Wan, R Sun, P Moharil, J Chen, Y Liu, X Song, Q Ao Journal of Leucocyte Biology 109 (2), 425-436, 2021 | 26 | 2021 |
| Eomes impedes durable response to tumor immunotherapy by inhibiting stemness, tissue residency, and promoting the dysfunctional state of intratumoral CD8+ T cells R Sun, Y Wu, H Zhou, Y Wu, Z Yang, Y Gu, J Jiang, B Lu, Y Zhu Frontiers in cell and developmental biology 9, 640224, 2021 | 26 | 2021 |
| The half-life-extended IL21 can be combined with multiple checkpoint inhibitors for tumor immunotherapy S Wu, R Sun, B Tan, B Chen, W Zhou, DS Gao, J Zhong, H Huang, ... Frontiers in Cell and Developmental Biology 9, 779865, 2021 | 25 | 2021 |
| IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts L Chen, H Huang, X Zheng, Y Li, J Chen, B Tan, Y Liu, R Sun, B Xu, ... Journal for ImmunoTherapy of Cancer 10 (9), e004585, 2022 | 24 | 2022 |
| Amphiregulin couples IL1RL1+ regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity R Sun, H Zhao, DS Gao, A Ni, H Li, L Chen, X Lu, K Chen, B Lu Science Advances 9 (34), eadd7399, 2023 | 20 | 2023 |
| A novel immunochemotherapy based on targeting of cyclooxygenase and induction of immunogenic cell death H Huang, Y Huang, Y Chen, Z Luo, Z Zhang, R Sun, Z Wan, J Sun, B Lu, ... Biomaterials 270, 120708, 2021 | 20 | 2021 |
| Targeting metabotropic glutamate receptor 4 for cancer immunotherapy Z Wan, R Sun, YW Liu, S Li, J Sun, J Li, J Zhu, P Moharil, B Zhang, P Ren, ... Science Advances 7 (50), eabj4226, 2021 | 14 | 2021 |
| Chronic activation of LXRα sensitizes mice to hepatocellular carcinoma Y Xie, R Sun, L Gao, J Guan, J Wang, A Bell, J Zhu, M Zhang, M Xu, P Lu, ... Hepatology Communications 6 (5), 1123-1139, 2022 | 10 | 2022 |
| Synergism between IL21 and anti-PD-1 combination therapy is underpinned by the coordinated reprogramming of the immune cellular network in the tumor microenvironment S Wu, H Huang, R Sun, DS Gao, F Ye, J Huang, E Li, A Ni, KGK Lu, ... Cancer research communications 3 (8), 1460-1472, 2023 | 8 | 2023 |
| Farnesylthiosalicylic acid-derivatized PEI-based nanocomplex for improved tumor vaccination Y Chen, Y Huang, H Huang, Z Luo, Z Zhang, R Sun, Z Wan, J Sun, B Lu, ... Molecular Therapy Nucleic Acids 26, 594-602, 2021 | 8 | 2021 |
| Activation of Liver X Receptor α Sensitizes Mice to T‐Cell Mediated Hepatitis L Gao, B Li, J Wang, D Shen, M Yang, R Sun, HC Tung, M Xu, S Ren, ... Hepatology Communications 4 (11), 1664-1679, 2020 | 7 | 2020 |
| Tumor-derived IL33 promotes tissue-resident CD8+ T cells and is required for checkpoint blockade tumor immunotherapy. Cancer Immunol Res 2020; 8 (11): 1381-92. doi: 10.1158 … L Chen, R Sun, J Xu, W Zhai, D Zhang, M Yang, C Yue, Y Chen, S Li, ... CIR-19-1024 PMID: 32917659, 0 | 6 | |
| Compositions and methods for treating cancer B Lu, R Sun US Patent App. 18/738,964, 2024 | | 2024 |
| Tumor suppressor p53 deficiency increases tumor immunogenicity through promoting IL33-mediated anti-tumor immune responses Y Li, DS Gao, L Yi, F Gao, R Sun, KK Lu, J Xu, J Shoush, Z Kykrou, ... bioRxiv, 2022.09. 11.507505, 2022 | | 2022 |
Binfeng LuProfessor, University of Pittsburgh School of Medicineכתובת אימייל מאומתת בדומיין pitt.edu